|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Schiller JH, Harrington D, Belani CP, et
al: Comparison of four chemotherapy regimens for advanced
non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002.
View Article : Google Scholar
|
|
3
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pao W, Wang TY, Riely GJ, et al: KRAS
mutations and primary resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jackman D, Pao W, Riely GJ, et al:
Clinical definition of acquired resistance to epidermal growth
factor receptor tyrosine kinase inhibitors in non-small-cell lung
cancer. J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
8
|
Gloeckler Ries LA, Reichman ME, Lewis DR,
Hankey BF and Edwards BK: Cancer survival and incidence from the
Surveillance, Epidemiology, and End Results (SEER) program.
Oncologist. 8:541–552. 2003.
|
|
9
|
Schiff PB, Fant J and Horwitz SB:
Promotion of microtubule assembly in vitro by taxol. Nature.
277:665–667. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gligorov J and Lotz JP: Preclinical
pharmacology of the taxanes: implications of the differences.
Oncologist. 9(Suppl 2): 3–8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246.
2003.
|
|
12
|
Kris MG, Natale RB, Herbst RS, et al:
Efficacy of gefitinib, an inhibitor of the epidermal growth factor
receptor tyrosine kinase, in symptomatic patients with non-small
cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ciardiello F, Caputo R, Bianco R, et al:
Antitumor effect and potentiation of cytotoxic drugs activity in
human cancer cells by ZD-1839 (Iressa), an epidermal growth factor
receptor-selective tyrosine kinase inhibitor. Clin Cancer Res.
6:2053–2063. 2000.
|
|
14
|
Sirotnak FM, Zakowski MF, Miller VA, Scher
HI and Kris MG: Efficacy of cytotoxic agents against human tumor
xeno-grafts is markedly enhanced by coadministration of ZD1839
(Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res.
6:4885–4892. 2000.PubMed/NCBI
|
|
15
|
Herbst RS, Giaccone G, Schiller JH, et al:
Gefitinib in combination with paclitaxel and carboplatin in
advanced non-small-cell lung cancer: a phase III trial - INTACT 2.
J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Giaccone G, Herbst RS, Manegold C, et al:
Gefitinib in combination with gemcitabine and cisplatin in advanced
non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin
Oncol. 22:777–784. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gandara D, Narayan S, Lara PN Jr, et al:
Integration of novel therapeutics into combined modality therapy of
locally advanced non-small cell lung cancer. Clin Cancer Res.
11:5057s–5062s. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gandara DR and Gumerlock PH: Epidermal
growth factor receptor tyrosine kinase inhibitors plus
chemotherapy: case closed or is the jury still out? J Clin Oncol.
23:5856–5858. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Magné N, Fischel JL, Dubreuil A, et al:
Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with
cytotoxic treatment in human head and neck cancer. Br J Cancer.
86:819–827. 2002.
|
|
21
|
Xu JM, Azzariti A, Colucci G and Paradiso
A: The effect of gefitinib (Iressa, ZD1839) in combination with
oxaliplatin is schedule-dependent in colon cancer cell lines.
Cancer Chemother Pharmacol. 52:442–448. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Higgins B, Kolinsky K, Smith M, et al:
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in
combination in human non-small cell lung cancer tumor xenograft
models. Anticancer Drugs. 15:503–512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herbst RS, Prager D, Hermann R, et al:
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774)
combined with carboplatin and paclitaxel chemotherapy in advanced
non-small-cell lung cancer. J Clin Oncol. 23:5892–5929. 2005.
View Article : Google Scholar
|
|
24
|
Gatzemeier U, Pluzanska A, Szczesna A, et
al: Phase III study of erlotinib in combination with cisplatin and
gemcitabine in advanced non-small-cell lung cancer: the Tarceva
Lung Cancer Investigation Trial. J Clin Oncol. 25:1545–1552. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng H, An SJ, Zhang XC, et al: In vitro
sequence-dependent synergism between paclitaxel and gefitinib in
human lung cancer cell lines. Cancer Chemother Pharmacol.
67:637–646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Davies AM, Ho C, Lara PN Jr, Mack P,
Gumerlock PH and Gandara DR: Pharmacodynamic separation of
epidermal growth factor receptor tyrosine kinase inhibitors and
chemotherapy in non-small-cell lung cancer. Clin Lung Cancer.
7:385–388. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li T, Ling YH, Goldman ID and Perez-Soler
R: Schedule-dependent cytotoxic synergism of pemetrexed and
erlotinib in human non-small cell lung cancer cells. Clin Cancer
Res. 13:3413–3422. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cross TG, Scheel-Toellner D, Henriquez NV,
Deacon E, Salmon M and Lord JM: Serine/threonine protein kinases
and apoptosis. Exp Cell Res. 256:34–41. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan F, Tian J, Zhang X, et al: Synergistic
interaction between sunitinib and docetaxel is sequence dependent
in human non-small lung cancer with EGFR TKIs-resistant mutation. J
Cancer Res Clin Oncol. 137:1397–1408. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Van Schaeybroeck S, Karaiskou-McCaul A,
Kelly D, et al: Epidermal growth factor receptor activity
determines response of colorectal cancer cells to gefitinib alone
and in combination with chemotherapy. Clin Cancer Res.
11:7480–7489. 2005.
|
|
31
|
Van Schaeybroeck S, Kyula J, Kelly DM, et
al: Chemotherapy-induced epidermal growth factor receptor
activation determines response to combined gefitinib/chemotherapy
treatment in non-small cell lung cancer cells. Mol Cancer Ther.
5:1154–1165. 2006.
|
